Trial Profile
06-benzylguanine (BG) and Temozolomide (TMZ) Therapy of Glioblastoma Multiforme (GBM) in Patients With MGMT Positive Tumors With Infusion of Autologous P140KMGMT+ Hematopoietic Progenitors to Protect Hematopoiesis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Mar 2023
Price :
$35
*
At a glance
- Drugs LG 631 (Primary) ; Benzylguanine; Temozolomide; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- 01 Mar 2023 Status changed from active, no longer recruiting to completed.
- 06 May 2022 Planned End Date changed from 1 Mar 2022 to 1 Sep 2022.
- 20 Dec 2021 Planned End Date changed from 1 Nov 2021 to 1 Mar 2022.